Top Markets
#1 Wiki Cat Wiki Cat +55.96%
#2 Siren Siren +35.80%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.44%
#4 Ribbita by Virtuals Ribbita by Virtuals +22.19%
#5 PulseChain PulseChain +18.13%
#6 Velvet Velvet +17.48%
#7 KUB Coin KUB Coin +16.83%
#8 OpenEden OpenEden +16.69%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +16.55%
#10 The Grays Currency The Grays Currency +16.32%
Coin of the day
Wiki Cat Wiki Cat
設定
言語
日本
通貨
USD
テーマ
Celyad Oncology S.A. Celyad Oncology S.A.

Celyad Oncology S.A.

CYAD
株式のランク #30914
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
株価
$0.343985
時価総額
$15.40M
変化（1日）
3.94%
変化（1年）
-25.19%
国
BE
取引 Celyad Oncology S.A. (CYAD)

カテゴリー

Healthcare
Celyad Oncology S.A.（CYAD）の配当利回りの履歴
Celyad Oncology S.A.（銘柄コード: CYAD）の配当利回り（TTM）は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Celyad Oncology S.A.（CYAD）の2026から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
年 配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り（TTM）
企業 配当利回り 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
0.48%
BE